A randomized trial to evaluate attitudes regarding pharmacogenomics among pregnant and pediatric populations: design and baseline characteristics.
Clinical Snapshot
PICO Framework
| P — Population | Pregnant individuals and families/guardians of children aged 0-16 years with chronic health conditions |
| I — Intervention | Educational video about pharmacogenomics testing with return of results |
| C — Comparator | Pharmacogenomics test results alone (without educational video) |
| O — Outcomes | Knowledge and attitudes regarding pharmacogenomics testing, understanding and perceived utility of PGx testing |
Bottom Line
This randomized trial design addresses a critical gap in pharmacogenomics research by focusing on pregnant women and children - populations typically excluded from PGx studies. The study compares educational video plus results versus results alone to assess impact on patient knowledge and attitudes toward pharmacogenomic testing. While the intervention appears feasible and low-risk, this paper only presents the study design and baseline characteristics. The actual effectiveness of educational interventions on patient understanding remains to be demonstrated. The research is important for informing clinical implementation of pharmacogenomics in vulnerable populations, but clinicians should await the full results before drawing conclusions about optimal patient education strategies for PGx testing.
Key Findings
P Value: Not yet reported
Effect Size: Not yet reported
Primary Outcome: Not yet reported - this is a design and baseline characteristics paper
Nnt Or Sensitivity: Not applicable - this is an educational intervention study
Confidence Interval: Not yet reported
Clinical Application
Educational video intervention is highly feasible and low-cost to implement in clinical practice Relevant to Australian practice as pharmacogenomics becomes more integrated into precision medicine. Could inform TGA and PBS considerations for PGx testing implementation Pregnant women and families with children having chronic health conditions considering pharmacogenomic testing
Abstract
Pharmacogenomics (PGx) is a key component of precision medicine, yet most PGx studies exclude pregnant people and children. The VICE (Vanderbilt Integrated Center of Excellence)-MPRINT (Maternal and Pediatric Precision in Therapeutics): Maternal and Pediatric Pharmacogenetics Trial is a single-center, randomized control trial to assess how PGx testing and return of results influence patients' understanding and perceived utility of PGx testing in a pregnancy and pediatric cohort. Pregnant individuals and families or guardians of children with a chronic health condition aged 0-16 were recruited. We assessed participants' knowledge and attitudes regarding PGx testing at baseline and after receiving results with patient-friendly interpretations. Cases received an educational video about PGx testing with return of results. Controls received PGx test results alone. We aimed to determine perspectives regarding PGx in these understudied populations with the goal of promoting research and clinical implementation of PGx for pregnant women and children.
References
- 1.Sundermann, A. C., Marryshow Batson, S. E., Jasper, E. A., Jones, S. H., Fountain, D. F., Liu, M., Sunthankar, S. D., & Velez Edwards, D. R. (2026). A randomized trial to evaluate attitudes regarding pharmacogenomics among pregnant and pediatric populations: design and baseline characteristics. The Pharmacogenomics Journal. https://doi.org/10.1093/jalm/jfad064
Related Research
Acta obstetricia et gynecologica Scandinavica
ChatGPT in urogynecology: Comparing large language model responses to human experts
3 Aug 2026
Ultrasound in medicine & biology
A Systematic Review: The Application of Attention Mechanisms in Medical Ultrasound Image Processing
2 Aug 2026
Preventing chronic disease
Reducing Rates of Cesarean Delivery in Rural US Communities: A Systematic Review of Interventions and Approaches to Care
31 July 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service